09926.HK
Akeso, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 83.50
−1.82%Year over year
Reported trailing growth
- Revenue
- +35.3%
- EBITDA
- -27.6%
- EBIT
- -8.5%
- EPS
- -8.3%
- Free cash flow
- —
- Operating cash flow
- -54.0%
Forward estimates
Based on analyst estimates
- Revenue
- -73.0%
- EBITDA
- +183.7%
- EPS
- +93.1%
Three-year CAGR
- Revenue
- +52.6%
- EBITDA
- -22.4%
- EBIT
- -61.0%
- Net income
- —
- EPS
- -100.0%
- Free cash flow
- -64.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026